X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
GSK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs3,838399-   
Low Rs2,637288-   
Sales per share (Unadj.) Rs354.2118.6-  
Earnings per share (Unadj.) Rs39.8-29.9-  
Cash flow per share (Unadj.) Rs42.9-24.8-  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.993.1-  
Shares outstanding (eoy) m84.70168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.12.9 315.9%   
Avg P/E ratio x81.4-11.5 -709.1%  
P/CF ratio (eoy) x75.5-13.9 -545.0%  
Price / Book Value ratio x13.73.7 370.7%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,21657,925 473.4%   
No. of employees `0004.74.3 109.4%   
Total wages/salary Rs m4,8303,636 132.9%   
Avg. sales/employee Rs Th6,387.04,663.4 137.0%   
Avg. wages/employee Rs Th1,028.3846.8 121.4%   
Avg. net profit/employee Rs Th717.1-1,175.1 -61.0%   
INCOME DATA
Net Sales Rs m30,00020,020 149.8%  
Other income Rs m728140 519.4%   
Total revenues Rs m30,72820,160 152.4%   
Gross profit Rs m4,190-3,469 -120.8%  
Depreciation Rs m263864 30.4%   
Interest Rs m0542 0.0%   
Profit before tax Rs m4,655-4,736 -98.3%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744296 589.4%   
Profit after tax Rs m3,368-5,045 -66.8%  
Gross profit margin %14.0-17.3 -80.6%  
Effective tax rate %37.5-6.2 -599.6%   
Net profit margin %11.2-25.2 -44.6%  
BALANCE SHEET DATA
Current assets Rs m16,74214,663 114.2%   
Current liabilities Rs m7,2028,250 87.3%   
Net working cap to sales %31.832.0 99.3%  
Current ratio x2.31.8 130.8%  
Inventory Days Days52111 46.7%  
Debtors Days Days21124 16.8%  
Net fixed assets Rs m8,6358,547 101.0%   
Share capital Rs m84793 911.2%   
"Free" reserves Rs m19,2220-   
Net worth Rs m20,06915,714 127.7%   
Long term debt Rs m105,522 0.2%   
Total assets Rs m30,03829,684 101.2%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.7 148.1%   
Return on assets %11.2-15.2 -73.9%  
Return on equity %16.8-32.1 -52.3%  
Return on capital %25.5-19.8 -128.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,3601,709 138.1%  
From Investments Rs m3,008-525 -573.3%  
From Financial Activity Rs m-5,1085,012 -101.9%  
Net Cashflow Rs m2606,196 4.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.5 Rs / ZAR

Compare GSK PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: AUROBINDO PHARMA  VENUS REMEDIES  DR. REDDYS LAB  DR. DATSONS LABS  DISHMAN PHARMA  



Today's Market

Sensex Trades in Green; Metal Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading marginally above the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 21, 2018 03:03 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS